Definitive Contract 75N93020C00011
Award Date
6/1/20
Potential Completion Date
5/31/22
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
Zymeron Corporation has been awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Zymeron will develop a novel nanoparticle delivery system to elicit a potent and long-lasting antibody response and broad neutralizing activity against HIV, as requested under the Centers for Disease Control and Prevention and NIH solicitation seeking...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
This is a $300,000.00 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Cure Systems LLC, a small disadvantaged business located in Newton, MA. The contract is for the development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies" and is related to NIAID's SBIR program objectives to stimulate technological...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Acousticabio, Inc., a small business in Cambridge, MA. The contract, valued at $295,116, is for the development of "HIGH-DOSE AND SUSTAINED DELIVERY OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES VIA SUBCUTANEOUS INJECTION OF HYDROGEL-BASED MICROPARTICLE FORMATIONS". This contract is...
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Neovaxsyn Inc., a minority-owned small disadvantaged business located in Ames, Iowa. The $300,000 firm-fixed-price contract supports the development of innovative HIV/AIDS vaccine technologies, including the use of nanoparticle delivery systems and strategies to induce broadly...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) Program. The objective is to develop a new chemical entity drug for proteolytic degradation of HIV Gag proteins. The contract is a Firm Fixed Price Definitive Contract with a potential value of $299,794.00 and a...